Want to see PSNL full AI Analyst Report?
Top Page
Personalis
(NASDAQ:PSNL)
Select Model
Select Model
Rating:50Neutral
Price Target:
$16.00
▼(-7.25% Downside)
Action:Reiterated
Date:10/07/26
PSNL’s score is held back primarily by weak financial performance: falling TTM revenue, negative gross profit, very large losses, and ongoing cash burn. Technicals are neutral with some longer-term trend support but no strong momentum. Valuation is difficult to justify on earnings given the negative P/E and no dividend. Offsetting these risks, recent corporate events are a meaningful positive, led by the Tempus AI acquisition process and additional VA contract funding.
Positive Factors
Strategic merger progress
The merger’s regulatory progress increases the likelihood that Personalis will join Tempus, potentially adding Tempus’s scale, data and AI-enabled commercialization to its oncology testing platform. That could broaden market access and support durable adoption, although shareholder approval and other closing conditions remain.
Negative Factors
Revenue and gross-profit deterioration
The sharp revenue decline, following earlier modest growth, signals weakened commercial momentum in the core testing and analysis business. Negative gross profit also indicates current service economics are unfavorable, making sustainable scaling harder and increasing pressure to improve pricing, utilization, or operating efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic merger progress
The merger’s regulatory progress increases the likelihood that Personalis will join Tempus, potentially adding Tempus’s scale, data and AI-enabled commercialization to its oncology testing platform. That could broaden market access and support durable adoption, although shareholder approval and other closing conditions remain.
Read all positive factors
Personalis Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across Personalis’ business lines (for example sequencing services, clinical assays, and biopharma partnerships), revealing which activities drive growth, margins, and recurring income. Highlights dependence on large customers or one-off projects versus scalable, repeatable contracts and shows whether the company is moving toward higher-value clinical products that can boost long-term profitability and reduce revenue volatility.
Breaks down revenue across Personalis’ business lines (for example sequencing services, clinical assays, and biopharma partnerships), revealing which activities drive growth, margins, and recurring income. Highlights dependence on large customers or one-off projects versus scalable, repeatable contracts and shows whether the company is moving toward higher-value clinical products that can boost long-term profitability and reduce revenue volatility.
Data provided by:
The Fly
The FlyPersonalis (PSNL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.71B
Dividend YieldN/A
Average Volume (3M)2.20M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth-13.26%
EPS Growth14.26%
CountryUS
Employees260
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.09
Shares Outstanding106,799,870
10 Day Avg. Volume2,097,407
30 Day Avg. Volume2,198,277
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)10.20
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue17.77
Enterprise Value/Gross Profit140.08
Enterprise Value/Ebitda-12.73
Forecast
1Y Price Target
$16.83Price Target Upside-2.42% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$80.87M
Personalis Business Overview & Revenue Model
Company Description
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic r...
How the Company Makes Money
Personalis makes money primarily by selling testing and analysis services that generate multi-omic (e.g., DNA/RNA sequencing and related analytics) data and insights for customers, especially biopharmaceutical companies and research organizations ...
Personalis Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.Positive Updates
Rapid clinical volume acceleration
Delivered >7,800 clinical tests in Q1 2026, a 26% sequential increase vs Q4 and a 258% year-over-year increase, with a 2026 annual volume target of 43,000 to 45,000 tests.
Negative Updates
Near-term revenue mix shift and year-over-year decline
Total Q1 revenue was $15.5M, ~25% lower than Q1 2025, reflecting an intentional migration away from lower-margin legacy/enterprise revenue and the expected decline in Moderna-related revenue after a large Phase 3 enrollment ended.
Read all updates
Q1-2026 Updates
Positive
Negative
Rapid clinical volume acceleration
Delivered >7,800 clinical tests in Q1 2026, a 26% sequential increase vs Q4 and a 258% year-over-year increase, with a 2026 annual volume target of 43,000 to 45,000 tests.
Read all positive updates
Company Guidance
Personalis reaffirmed full‑year 2026 revenue guidance of $78–$80 million, expecting clinical revenue of $10–$11M (breast and lung surveillance), pharma/tests and other customers of $55–$56M, population sequencing/enterprise ~ $13M, strategic revenue to more than double to $30–$32M and biopharma MRD revenue of $20–$21M, and it projects 43,000–45,000 clinical tests for 2026. Management expects full‑year gross margin of 15%–20% (Q1 was 1.8% with >2,000 bps dilution from unreimbursed tests and the first half as the trough), a net loss of ~ $105M, and cash usage of ~ $100M; Q1 results cited $15.5M revenue, >7,800 clinical tests (+26% sequential, +258% YoY), $4.5M strategic revenue, $3.1M MRD revenue, $1.4M clinical revenue, operating expenses of $32.4M (R&D $14.5M; SG&A $17.9M), net loss $30.0M, and $233.2M cash and short‑term investments after ~$28M cash used (including ~$5M one‑time incentive).Personalis Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.67M | 69.65M | 84.61M | 73.48M | 65.05M | 85.49M |
| Gross Profit | 8.84M | 15.78M | 26.82M | 18.21M | 13.35M | 31.66M |
| EBITDA | -97.22M | -71.00M | -70.30M | -96.81M | -104.64M | -59.01M |
| Net Income | -107.18M | -81.27M | -81.28M | -108.30M | -113.31M | -65.23M |
Balance Sheet | ||||||
| Total Assets | 312.13M | 334.16M | 270.27M | 225.10M | 292.70M | 396.53M |
| Cash, Cash Equivalents and Short-Term Investments | 212.66M | 239.95M | 185.01M | 114.18M | 167.66M | 287.06M |
| Total Debt | 38.00M | 39.95M | 44.25M | 47.73M | 48.65M | 58.33M |
| Total Liabilities | 76.97M | 72.98M | 67.31M | 95.66M | 74.56M | 86.23M |
| Stockholders Equity | 235.16M | 261.19M | 202.96M | 129.44M | 218.14M | 310.30M |
Cash Flow | ||||||
| Free Cash Flow | -100.97M | -79.45M | -46.75M | -67.17M | -120.13M | -81.91M |
| Operating Cash Flow | -92.30M | -74.95M | -45.15M | -56.26M | -70.23M | -70.83M |
| Investing Cash Flow | -3.50M | -22.57M | -35.07M | 13.10M | 52.54M | -60.07M |
| Financing Cash Flow | 136.40M | 130.34M | 114.67M | 11.03M | 1.37M | 169.70M |
Personalis Technical Analysis
Neutral
17.25
Price Trends
15.81
Positive
13.78
Positive
10.73
Positive
Market Momentum
0.04
Positive
47.26
Neutral
35.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Neutral. The current price of 17.25 is above the 20-day moving average (MA) of 16.25, above the 50-day MA of 15.81, and above the 200-day MA of 10.73, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.26 is Neutral, neither overbought nor oversold. The STOCH value of 35.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PSNL.
Personalis Risk Analysis
Personalis disclosed 78 risk factors in its most recent earnings report. Personalis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Personalis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $3.64B | 31.41 | 8.64% | ― | 17.28% | 323.64% | |
60 Neutral | $22.47B | -47.99 | 211.46% | ― | 42.74% | -4.60% | |
55 Neutral | $162.93M | -1.61 | -12.97% | ― | -3.65% | 51.30% | |
52 Neutral | $2.10B | -8.24 | -6.31% | 0.75% | 11.19% | 50.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.71B | -14.68 | -46.47% | ― | -13.26% | 14.26% |
* Healthcare Sector Average
PSNL
Personalis
16.00
7.77
94.41%
VCYT
Veracyte
45.23
11.14
32.68%
NEO
NeoGenomics
16.35
7.01
75.05%
GH
Guardant Health
167.47
105.74
171.29%
BNR
Burning Rock Biotech
15.49
6.90
80.33%
FRNM
Freenome Inc
15.78
5.14
48.31%
Personalis Corporate Events
M&A TransactionsRegulatory Filings and Compliance
Personalis-Tempus merger clears key regulatory milestone
Positive
Oct 6, 2026
On July 20, 2026, Personalis, Inc. entered into a merger agreement with Tempus AI, Inc., under which a two-step merger structure will ultimately make Personalis a wholly owned subsidiary of Tempus. The transaction advanced on October 2, 2026, when...
Business Operations and StrategyFinancial Disclosures
Personalis secures new Million Veteran Program task order
Positive
Aug 20, 2026
On August 20, 2026, Personalis, Inc. reported receiving a new task order under its existing contract with the U.S. Department of Veterans Affairs for the Million Veteran Program. Effective September 30, 2026, the order is valued at up to $18.3 mil...
M&A Transactions
Personalis to Be Acquired by Tempus AI in Merger
Positive
Jul 20, 2026
On July 20, 2026, Personalis entered into a definitive agreement to be acquired by Tempus AI through a two-step merger under which Personalis will ultimately become a wholly owned subsidiary of Tempus. Personalis stockholders will receive Tempus C...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Personalis to be acquired by Tempus AI in merger
Positive
Jul 20, 2026
On July 20, 2026, Personalis announced a definitive agreement to be acquired by Tempus AI, in a two-step merger that will ultimately make Personalis a wholly owned subsidiary of Tempus. The all-stock transaction values Personalis at $16.25 per sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.